| 191 | 0 | 266 |
| 下载次数 | 被引频次 | 阅读次数 |
中枢神经系统生殖细胞肿瘤是常见于儿童和青少年的中枢神经系统恶性肿瘤，其中纯生殖细胞瘤对放疗和化疗的敏感性显著优于其他类型，故其他类型统称为非生殖细胞瘤性生殖细胞肿瘤（NGGCT）。中枢神经系统NGGCT的国际标准治疗采用手术、化疗与放疗相结合的综合治疗策略，但其亚型多样、病情复杂，治疗方案需结合患者年龄、临床症状、肿瘤标志物表达、肿瘤部位、大小及病理类型等因素个体化制定。为规范诊疗流程，中华医学会神经外科分会小儿神经外科学组基于国内外临床研究与实践经验，制定了中国儿童及青少年中枢神经系统NGGCT诊治指南。本指南涵盖3岁以上初发与复发患者的综合诊疗方案，旨在提升国内中枢神经系统NGGCT患者的治疗效果并改善预后。
Abstract：Central nervous system germ cell tumors are common malignant tumors in children and adolescents. Pure germ cell tumors are significantly more sensitive to radiotherapy and chemotherapy than other types of germ cell tumors, so other types of germ cell tumors are collectively referred to as non-germinomatous germ cell tumors(NGGCT). The internationally recognized treatment method for central nervous system NGGCT is an integrated treatment approach combining surgery, chemotherapy, and radiotherapy. However, due to the diversity and complexity of its subtypes, treatment strategies also vary based on multiple related factors such as patient age, clinical symptoms, tumor marker expression, tumor location, tumor size, and pathological type. To standardize the diagnosis and treatment of central nervous system NGGCT, the Pediatric Neurosurgery Group of the Chinese Medical Association's Neurosurgery Branch has developed guidelines for the diagnosis and treatment of central nervous system NGGCT in Chinese children and adolescents based on domestic and international clinical research and experience. This guideline covers the integrated diagnosis and treatment plans for primary and recurrent central nervous system NGGCT in patients over 3 years old, hoping to further improve the treatment outcomes and prognosis of patients with central nervous system NGGCT in China.
[1]Villano JL, Propp JM, Porter KR, et al. Malignant pineal germ-cell tumors:an analysis of cases from thnree tumor registries[J]. Neuro Oncol, 2008, 10(2):121-130. DOI:10.1215/15228517-2007-054.
[2]Goodwin TL, Sainani K, Fisher PG. Incidence patterns of central nervous system germ cell tumors:a seer study[J]. J Pediatr Hematol Oncol,2009, 31(8):541-544. DOI:10.1097/MPH.0b013e3181983af5.
[3]Ostrom QT, Cioffi G, Waite K, et al. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018[J]. Neuro Oncol, 2021, 23(12):1-105.DOI:10.1093/neuonc/noab200.
[4]Nakamura H, Takami H, Yanagisawa T, et al. The Japan society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors[J]. Neuro Oncol, 2022, 24(4):503-515. DOI:10.1093/neuonc/noab242.
[5]Frappaz D, Dhall G, Murray MJ, et al. EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults[J].Neuro Oncol, 2022, 24(4):516-527. DOI:10.1093/neuonc/noab252.
[6]Committee of Brain Tumor Registry of J. Report of brain tumor registry of Japan(1969-1996)[J]. Neurol Med Chir(Tokyo), 2003, 43:1-111.
[7]Huang X, Zhang R, Zhou LF. Grading system for diagnosis and treatment of intracranial nongerminomatous malignant germ cell tumors[J]. Zhonghua Yi Xue Za Zhi, 2009, 89(33):2333-2336.
[8]Bowzyk AL-Naeeb A, Murray M, Horan G, et al. Current management of intracranial germ cell tumours[J]. Clin Oncol(R Coll Radiol),2018, 30(4):204-214. DOI:10.1016/j.clon.2018.01.009.
[9]Biassoni V, Schiavello E, Gandola L, et al. Secreting germ cell tumors of the central nervous system:a long-term follow-up experience[J].Cancers(Basel), 2020, 12(9):2688. DOI:10.3390/cancers12092688.
[10]Calaminus G, Bamberg M, Harms D, et al. AFP/beta-HCG secreting CNS germ cell tumors:long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89[J]. Neuropediatrics, 2005, 36(2):71-77. DOI:10.1055/s-2005-837582.
[11]Michaiel G, Strother D, Gottardo N, et al. Intracranial growing teratoma syndrome(iGTS):an international case series and review of the literature[J]. J Neurooncol, 2020, 147(3):721-730. DOI:10.1007/s11060-020-03486-9.
[12]Goldman S, Bouffet E, Fisher PG, et al. Phase II trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors:a children's oncology group study[J]. J clin oncol, 2015,33(22):2464-2471. DOI:10.1200/JCO.2014.59.5132.
[13]Abu Arja MH, Bouffet E, Finlay JL, et al. Critical review of the management of primary central nervous nongerminomatous germ cell tumors[J]. Pediatr Blood Cancer, 2019, 66(6):e27658. DOI:10.1002/pbc.27658.
[14]Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial[J]. Neuro Oncol, 2017, 19(12):1661-1672. DOI:10.1093/neuonc/nox122.
[15]Fangusaro J, Wu S, Macdonald S, et al. Phase II trial of response-based radiation therapy for patients with localized cns nongerminomatous germ cell tumors:a children's oncology group study[J]. J clin oncol, 2019, 37(34):3283-3290. DOI:10.1200/JCO.19.00701.
[16]Liang SY, Yang TF, Chen YW, et al. Neuropsychological functions and quality of life in survived patients with intracranial germ cell tumors after treatment[J]. Neuro Oncol, 2013, 15(11):1543-1551. DOI:10.1093/neuonc/not127.
[17]Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors:evidence from a large international database[J]. J clin oncol, 2011, 29(16):2178-2184. DOI:10.1200/JCO.2010.32.6678.
[18]Loehrer PJSR, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor[J]. J clin oncol, 1998, 16(7):2500-2504. DOI:10.1200/JCO.1998.16.7.2500.
[19]Kurobe M, Kawai K, Oikawa T, et al. Paclitaxel, ifosfamide, and cisplatin(TIP)as salvage and consolidation chemotherapy for advanced germ cell tumor[J]. J Cancer Res Clin Oncol, 2015, 141(1):127-133.DOI:10.1007/s00432-014-1760-x.
[20]2Selle F, Wittnebel S, Biron P, et al. A phase II trial of high-dose chemotherapy(HDCT)supported by hematopoietic stem-cell transplantation(HSCT)in germ-cell tumors(GCTs)patients failing cisplatin-based chemotherapy:the Multicentric TAXIF II study[J]. Ann Oncol, 2014, 25(9):1775-1782. DOI:10.1093/annonc/mdu198.
[21]Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours[J]. Ann Oncol, 2005, 16(7):1152-1159. DOI:10.1093/annonc/mdi228.
[22]Lotz JP, Bui B, Gomez F, et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three highdose chemotherapy regimens supported by autologous stem cell transplantation results of the phase II multicentric TAXIF trial[J]. Ann Oncol, 2005, 16(3):411-418. DOI:10.1093/annonc/mdi087.
[23]Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors:results and prognostic factor analysis[J]. J clin oncol, 2010, 28(10):1706-1713. DOI:10.1200/JCO.2009.25.1561.
[24]Chevreau C, Massard C, Flechon A, et al. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors[J].Cancer Med, 2021, 10(7):2250-2258. DOI:10.1002/cam4.3687.
[25]Huang X, Zhang R, Zhou LF. Diagnosis and treatment of intracranial immature teratoma[J]. Pediatr Neurosurg, 2009, 45(5):354-360. DOI:10.1159/000257524.
基本信息:
中图分类号:R739.4
引用信息:
[1]中华医学会神经外科分会小儿神经外科学组 ,马杰,陈忠平,等.中国儿童及青少年中枢神经系统非生殖细胞瘤性生殖细胞肿瘤诊治指南（2026版）[J].中华神经外科疾病研究杂志,2026,20(02):8-15.
基金信息:
国家重点研发计划（2022YFC2705002）; 国家自然科学基金（8227102214）
2026-02-04
2026-02-04